Drozitumab
- Generic Name
- Drozitumab
A Study of PRO95780 Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated, Locally Advanced, Recurrent, and Metastatic Colorectal Cancer (APM4566g)
Phase 1
Completed
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- First Posted Date
- 2009-02-25
- Last Posted Date
- 2022-12-13
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT00851136
A Study of PRO95780 in Patients With Advanced Chondrosarcoma (APM4171g)
- First Posted Date
- 2007-10-15
- Last Posted Date
- 2022-12-13
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT00543712
- Locations
- 🇺🇸
Sarcoma Oncology Center, Santa Monica, California, United States
🇦🇺Peter MacCallum Cancer Centre, Melbourne, Australia
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
A Study of PRO95780 in Combination With Rituximab in Patients With Non-Hodgkin's Lymphoma That Has Progressed Following Previous Rituximab Therapy (APM4083g)
- First Posted Date
- 2007-08-16
- Last Posted Date
- 2017-06-06
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 49
- Registration Number
- NCT00517049
A Study of PRO95780 in Combination With Cetuximab and Irinotecan Chemotherapy or the FOLFIRI Regimen With Bevacizumab in Patients With Previously Treated Metastatic Colorectal Cancer (APM4187g)
Phase 1
Completed
- Conditions
- Colorectal Cancer
- Interventions
- First Posted Date
- 2007-07-06
- Last Posted Date
- 2017-05-19
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT00497497
A Study of PRO95780 in Patients With Previously Untreated, Advanced-Stage Non-Small Cell Lung Cancer (APM4074g)
Phase 2
Completed
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2007-05-31
- Last Posted Date
- 2017-05-18
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 128
- Registration Number
- NCT00480831
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath